Article info
ORIGINAL ARTICLE
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
- Address correspondence and reprint requests to: Gail L. Brown, MD, Telik, Inc., 3165 Porter Drive, Palo Alto, CA 94304, USA. Email: gbrown{at}telik.com
Citation
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
Publication history
- First published June 1, 2005.
Online issue publication
June 01, 2005
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2005 Blackwell Publishing Ltd.